目的 探討腹膜后囊性淋巴管瘤的CT診斷價值和治療方法。方法 回顧性分析2004年6月至2010年5月期間我院收治的5例經病理檢查證實的腹膜后囊性淋巴管瘤患者的臨床表現、CT影像特征、手術治療及術后隨訪的資料。結果 5例患者術前CT均診斷為囊性淋巴管瘤，均行手術完整切除腫瘤，術后病理結果均證實為囊性淋巴管瘤。術后7 d順利出院，隨訪3個月～6年均無復發。結論 CT對腹膜后囊性淋巴管瘤的診斷具有重要意義，手術完整切除整個囊壁是治療及預防術后復發的最好方法。
目的探討胃底賁門癌患者行全胃切除術后消化道的重建方式。 方法總結我院1999年3月至2002年4月間采用經腹全胃切除保留幽門環間置空腸重建消化道手術的16例胃底賁門癌患者的臨床資料。 結果無一例手術死亡， 無吻合口漏及狹窄， 全組患者均治愈出院。 術后半年每餐進食200～300 g， 每日3～4次， 其中蛋白質1 g/（kg·d）， 總熱量為2 300～3 000 kcal，餐后無胸骨后灼痛，無膽汁返流現象及排空障礙。結論嚴格掌握手術適應證，保留幽門環間置空腸重建消化道能起到較好的效果。
Objective To evaluate whether jejunal interposition pouch (JIP) reconstruction is an ideal procedure of digestive tract reconstruction after total gastrectomy. Methods Ninetyfour patients after total gastrectomy had randomly divided into two groups, JIP group 42 cases and RouxenY pouch (RYP) group 52 cases. The gastrointestinal function improvement in body weight and nutritional parameters (serum albumin, hemoglobin level, and serum protein) were compared 1 year after surgery for the two groups. Results The nutritional condition of JIP group and RYP group after operation had improved (P＜0.01); and the condition of JIP group with fewer symptom problems demonstrated much more better than standard RYP group （P＜0.01）. Conclusion JIP that could obtain partly compensatory function after total gastrectomy is an ideal reconstruction.
Objective To assess the effect of astragaulus membranaceus in the treatment of pulmonary tuberculosis. Methods Through applying the methods provided by the Cochrane Collaboration, the randomized controlled trials (RCTs) or quasi-RCTs of astragaulus membranaceus in the treatment of pulmonary tuberculosis were searched in The Cochrane Library (Issue 3, 2010), CNKI (1991 to May 2010), VIP (1989 to May 2010), EMbase (1981 to May 2010), and PubMed (1981 to May 2010). Two reviewers independently screened the included studies, extracted the data, assessed the quality, and cross checked then. The RevMan 5.0 software was used to conduct meta-analyses. Results Twelve RCTs involving 1 054 patients were included. All trials were tested in the mainland China. The results of meta-analyses showed that: a) The astragaulus membranaceus could assist the conventional drug to cure pulmonary tuberculosis, promote sputum negative conversion, focal absorption and cavity reduction in lung; b) The astragaulus membranaceus could reduce the adverse reactions of the conventional drug; c) The astragaulus membranaceus combined with the conventional drug could improve the patients’ symptoms and signs; and d) The astragaulus membranaceus combined with the conventional drug could reduce the bacterial relapse rates in follow-up after treatment. Conclusion The current evidence shows that the astragaulus membranaceus has some effects and is relatively safe to treat pulmonary tuberculosis. However, it is far from enough to recommend astragaulus membranaceus as a conventional adjuvant therapy for pulmonary tuberculosis because of no sufficient evidence obtained from this study for its small sample and low methodology quality. Therefore, more double-blind multi-center RCTs with high quality, large sample, and adequate follow up are required for further verification.